Key result
TOP-EVs efficiently deliver target proteins including CRISPR/Cas9 intracellularly in vitro and into liver in vivo.
Why the study?
Effective methods for endogenous loading and unloading of target proteins inside extracellular vesicles are limited, hampering their application as therapeutic delivery vehicles.
Population
In vitro cell models and in vivo liver models
Comparison
TOP-EVs mediated protein delivery vs no or conventional EV delivery
Design
Preclinical experimental study
Authors
Loading...
May advance protein therapeutics for liver disease; leaves open clinical translation pending human studies.
TOP-EVs represent a versatile platform for efficient intracellular protein delivery in vitro and in vivo, potentially advancing the development of protein-based therapeutics.
Ilahibaks et al. (2023) studied this question. TOP-EVs (Technology of Protein delivery through Extracellular Vesicles) was evaluated on Intracellular protein delivery. TOP-EVs successfully mediated efficient intracellular delivery of target proteins, including Cre recombinase and CRISPR/Cas9, in vitro and in the liver in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: